Brigit Kyei-Baffour

Brigit Kyei-Baffour advises clients on issues related to reimbursement, policy, and market access strategies for diagnostic, medical device, and pharmaceutical companies.

She leverages her experience analyzing Medicare and commercial payer policies, supporting health systems with the implementation of bundled payment initiatives, and providing market access support for pharmaceutical and medical device companies.

Prior to joining Avalere, Brigit worked at The Lewin Group where she managed project tasks related to Medicare’s Comprehensive Care for Joint Replacement Model and Bundled Payments for Care Improvement Initiative and led the development of several outcomes-based quality measures. Prior, she held consulting roles in the Access and Commercial Strategy practice at Covance Market Access Services, Inc., where she conducted in-depth health policy analyses related to coverage and reimbursement issues within the commercial and public payer spaces.

Brigit holds an MBA in health management and policy from the George Washington University School of Business and a BS in economics from the Wharton School of the University of Pennsylvania.

Authored Content

Tune into our second episode in the Avalere Health Essential Voice podcast series focused on social determinants of health (SDOH). In this segment, Avalere experts from the Center for Healthcare Transformation and Market Access practices discuss the strategies for SDOH solutions, specifically in the manufacturer space.

As the economic and social impact of COVID-19 change how patients access and receive care, manufacturers and third-party suppliers must consider how to evolve their patient support programs to meet the shifting access and affordability needs of patients.

Tune in to hear the first episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 1, we’ll be focusing on the outpatient prospective payment system proposed rule, more informally known as the OPPS.

Avalere experts published a supplement in the June 2019 American Journal of Managed Care entitled “Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy.”

Recent developments in the specialty pharmaceutical marketplace merit distinct attention from manufacturers.